Table 1.

Association of novel loci and new independent SNPs wth risk of diffuse large B-cell lymphoma (DLBCL)

Location	Nearest gene(s)	SNP	Positiona	Risk alleleb	Other allele	RAFc	Stage	No. Cases/No. controls	OR	(95% CI)	P	Phet	I2
6p25.3	EXOC2	rs116446171	484,453	G	C	0.019	Stage 1	2,661/6,220	2.26	(1.82–2.81)	1.48×10−13
						0.018	Stage 2	1,194/1,443	2.70	(1.84–3.96)	3.99×10−7
						0.019	Stage 3	1,351/4,460	1.78	(1.29–2.46)	0.00040
							Combined	5,206/12,123	2.20	(1.87–2.59)	2.33×10−21	0.17	32.82
8q24.21	PVT1	rs13255292	129,076,573	T	C	0.321	Stage 1	2,661/6,221	1.19	(1.11–1.28)	1.25×10−6
						0.315	Stage 2	1,195/1,444	1.30	(1.14–1.47)	4.29×10−5
						0.330	Stage 3	1,322/4,498	1.22	(1.09–1.36)	0.001
							Combined	5,178/12,163	1.22	(1.15–1.29)	9.98×10−13	0.37	8.30
		rs4733601	129,269,466	A	G	0.477	Stage 1	2,661/6,221	1.19	(1.11–1.27)	4.22×10−7
						0.479	Stage 2	1,196/1,445	1.19	(1.05–1.33)	0.004
						0.487	Stage 3	1,337/4,523	1.19	(1.07–1.32)	0.0016
							Combined	5,194/12,189	1.18	(1.11–1.25)	3.63×10−11	0.09	43.85
6p21.33	HLA-B	rs2523607	31,322,790	A	T	0.120	Stage 1	2,661/6,221	1.45	(1.29–1.64)	7.10×10−10
						0.123	Stage 2	1,195/1,444	1.14	(0.96–1.35)	0.14
						0.109	Stage 3d	1,114/1,102	1.25	(1.04–1.51)	0.019
							Combined	4,970/8767	1.32	(1.21–1.44)	2.40×10−10	0.26	21.63
2p23.3	NCOA1	rs79480871	24694472	T	C	0.076	Stage 1	2,660/6,220	1.35	(1.17–1.55)	3.51×10−5
						0.057	Stage 2	1,195/1,443	1.56	(1.22–1.99)	0.00037
						0.063	Stage 3	1,344/4,524	1.19	(0.98–1.46)	0.084
							Combined	5,199/12,187	1.34	(1.21–1.49)	4.23×10−8	0.15	34.59

^aPosition according to human reference NCBI37/hg19;

^bAllele associated with an increased risk of DLBCL;

^cRisk allele frequency in controls;

^dNot genotyped in NCI Replication study.